The cardiorenal effects of chronic phosphodiesterase-v inhibition in preclinical diastolic dysfunction (stage b heart failure)

To determine if chronic phosphodiesterase-V (PDEV) inhibition with tadalafil will improve urinary sodium excretion, glomerular filtration rate (GFR), plasma cGMP and urinary cGMP excretion in response to volume expansion (VE) in patients with preclinical diastolic dysfunction (PDD) or stage B heart failure.

Source: Journal of Cardiac Failure - June 6, 2023 Category: Cardiology Authors: Shravya Vinnakota, Fadi W Adel, Paul M McKie, Christopher G Scott, Horng H Chen Source Type: research